Summary of Brain-Computer Interface Industry Insights Industry Overview - The brain-computer interface (BCI) industry has entered the 3.0 closed-loop era, with China keeping pace with the U.S. in both invasive and non-invasive technology paths. The industry is expected to reach commercialization and large-scale clinical key periods by 2026 [1][2][3]. - Non-invasive technology holds an 80% market share among companies due to its high safety and broad audience, making it the mainstream commercialization direction for the next 5-10 years, covering rehabilitation, consumer, and diagnostic markets [1][2]. Key Developments and Innovations - **Neuralink** has enabled blind patients to recognize object outlines, while domestic companies like Fudan University and Ming Vision Brain Machine are progressing in artificial retina clinical trials, with expectations to enter human clinical stages by 2027 [2]. - **Borycon** has completed over 20 clinical trials for upper limb rehabilitation and received the first Class III medical device certification in China for its hard dura mater external implant product, with a surgical cost of approximately 200,000 yuan [2][3]. - In lower limb rehabilitation, Fudan University and Onward have achieved significant clinical results, with the next goal being independent walking within 1-2 years [2][3]. - Language decoding projects have achieved over 70% accuracy in Chinese, with a target of 80-90% by 2026, while English decoding has reached 98% accuracy [2]. Technological Advancements - The BCI technology has evolved through three stages: - **1.0**: Brain perception (e.g., EEG) - **2.0**: Brain control (independent perception and control) - **3.0**: Real-time closed-loop systems that can decode signals and provide immediate feedback [4]. - The core technology areas include brain perception (visual reconstruction, language parsing, etc.) and brain control (various stimulation techniques) [4]. Competitive Landscape - Over 800 BCI companies exist globally, with about two-thirds located in China and the U.S. The industry chain structure follows a 1:2:7 ratio (upstream:midstream:downstream) [5]. - Upstream focuses on electrode and chip development (10% of companies), midstream on software and services (20%), and downstream applications (70%) [5]. - Domestic companies like Ladder Medical and Brain Tiger excel in flexible electrodes and chips, while listed companies primarily focus on downstream applications due to easier commercialization [5]. Investment Trends - Investment is shifting from high-risk invasive technologies to more certain non-invasive technologies, with 70% of capital directed towards downstream applications [1][5][6]. - The global market for BCIs is projected to reach $145 billion by 2040, with non-invasive technologies expected to capture 80% of the market share [15]. Regulatory and Policy Environment - In 2025, seven ministries in China released documents to address resource waste and lack of collaboration in the BCI industry, aiming to establish a guiding committee by 2026 to optimize resource allocation [12][13]. Challenges and Future Directions - The main challenges for invasive technologies include high costs and safety concerns, while non-invasive technologies are expected to dominate due to their broader application potential [9][15]. - AI algorithms are seen as a key variable in enhancing signal extraction quality and reducing model training cycles, which could significantly accelerate clinical adoption [20]. Conclusion - The BCI industry is rapidly evolving, with significant advancements in both invasive and non-invasive technologies. The focus is shifting towards non-invasive applications, which are expected to dominate the market in the coming years. The regulatory landscape is also adapting to support the industry's growth, while investment trends indicate a preference for safer, more commercially viable technologies.